NDARECTALENEMA
Approved
Dec 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
5/8 — Partial
MEDROL (methylprednisolone acetate) by Pfizer is clinical pharmacology glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids. Approved for dermatomyositis, polymyositis, systemic lupus erythematosus and 4 more indications. First approved in 1977.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEDROL is methylprednisolone acetate, a synthetic glucocorticoid administered as a rectal enema for anti-inflammatory and immunomodulatory effects. It treats autoimmune and inflammatory conditions including rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, asthma, and dermatomyositis by suppressing immune response and reducing inflammation across multiple organ systems.
$0.011BPart D
LOE ApproachingMature product in LOE-approaching stage with minimal Part D penetration signals declining team investment and focus on defensive positioning.
Mechanism of Action
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt retaining properties, are used in replacement therapy in adrenocortical deficiency states. Their synthetic…
Indications (7)
Worked on MEDROL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.